Nuvilex Inc. (NASDAQ:PMCB) Sees Large Increase in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 469,898 shares, an increase of 356.3% from the April 30th total of 102,979 shares. Based on an average trading volume of 382,797 shares, the days-to-cover ratio is currently 1.2 days. Approximately 4.9% of the company’s shares are short sold.

Nuvilex Price Performance

PMCB stock opened at $0.86 on Friday. The company has a market capitalization of $9.21 million, a PE ratio of -0.77 and a beta of 0.46. Nuvilex has a 12 month low of $0.63 and a 12 month high of $1.51. The firm’s 50-day moving average is $0.74 and its 200 day moving average is $0.78.

Wall Street Analysts Forecast Growth

PMCB has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Nuvilex to a “sell” rating in a research note on Saturday, January 31st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuvilex presently has a consensus rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.